BioCentury | Apr 6, 2019
Finance

Everybody up

...approves Rocklatan netarsudil/latanoprost to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Aeterna Zentaris Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...A) Strongbridge Biopharma plc (NASDAQ:SBBP) licensed U.S. and Canadian rights to Macrilen macimorelin acetate from Aeterna Zentaris Inc....
...Switzerland, U.S. $175.0 Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Rhopressa netasurdil Glaucoma or ocular hypertension U.S. $9.7 Aeterna Zentaris Inc....
BioCentury | Nov 30, 2018
Clinical News

CHMP backs first all-oral sleeping sickness treatment, extensions for Blincyto, Opdivo-Yervoy combo

...Approval" ). CHMP also recommended Macrilen macimorelin acetate, an oral ghrelin-mimetic growth hormone secretagogue from Aeterna Zentaris Inc....
...affect other trials of Tecentriq as a monotherapy or as part of a combination therapy. Aeterna Zentaris Inc....
...ARN-509 (Compound #), apalutamide (Generic), Erleada (Other) Fexinidazole Macrilen, macimorelin acetate (AEZS-130, ard-07, macrimorelin-ghst, EP01572, EP-1572, Solorel) Opdivo/Yervoy, nivolumab/ipilimumab Aeterna Zentaris Inc. Amgen...
BioCentury | Nov 16, 2018
Company News

CHMP backs first all-oral sleeping sickness treatment, extensions for Blincyto, Opdivo-Yervoy combo

...Approval" ). CHMP also recommended Macrilen macimorelin acetate, an oral ghrelin-mimetic growth hormone secretagogue from Aeterna Zentaris Inc....
...2017 for the indication (see "Strongbridge Hands Off Macrilen to Novo for Sizeable Return" ). Aeterna's...
...ARN-509 (Compound #), apalutamide (Generic), Erleada (Other) Fexinidazole Macrilen, macimorelin acetate (AEZS-130, ard-07, macrimorelin-ghst, EP01572, EP-1572, Solorel) Opdivo/Yervoy, nivolumab/ipilimumab Aeterna Zentaris Inc. Amgen...
BioCentury | Nov 2, 2018
Company News

Strongbridge hands off Macrilen to Novo for sizable return

...$24 million to Aeterna Zentaris Inc. (NASDAQ:AEZS; TSX:AEZS) for the Macrilen rights in January. On Oct. 31, Aeterna...
...$2.18 on NASDAQ and C$1.16 (69%) to C$2.85 in Toronto. Under its deal with Strongbridge, Aeterna...
...Aeterna has Macrilen in pediatric trials, and that Novo will assume Strongbridge's financial obligation to Aeterna...
BioCentury | Oct 31, 2018
Company News

Strongbridge hands off Macrilen to Novo for sizable return

...out $24 million to Aeterna Zentaris Inc. (NASDAQ:AEZS; TSX:AEZS) for the Macrilen rights in January. On Wednesday, Aeterna...
...$2.18 on NASDAQ and C$1.16 (69%) to C$2.85 in Toronto. Under its deal with Strongbridge, Aeterna...
...Aeterna has Macrilen in pediatric trials, and that Novo will assume Strongbridge's financial obligation to Aeterna...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

...to treat solid tumors with KRAS (K-Ras), BRAF or neuroblastoma Ras viral oncogene (NRAS) mutations. Aeterna Zentaris Inc....
BioCentury | Jul 6, 2018
Company News

Management tracks: Goldman Sachs, Acceleron

...Rapperswil, Switzerland) hired Richard Sachse as global CSO. He was SVP, CSO and CMO at Aeterna Zentaris Inc....
BioCentury | May 23, 2018
Distillery Techniques

Disease models

...compared with vehicle. Next steps could include using the model to screen other PCOS therapies. Aeterna Zentaris Inc....
BioCentury | Jan 9, 2018
Finance

Stars in China

...netarsudil 0.02% to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension Aeterna Zentaris Inc....
Items per page:
1 - 10 of 547
BioCentury | Apr 6, 2019
Finance

Everybody up

...approves Rocklatan netarsudil/latanoprost to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Aeterna Zentaris Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...A) Strongbridge Biopharma plc (NASDAQ:SBBP) licensed U.S. and Canadian rights to Macrilen macimorelin acetate from Aeterna Zentaris Inc....
...Switzerland, U.S. $175.0 Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Rhopressa netasurdil Glaucoma or ocular hypertension U.S. $9.7 Aeterna Zentaris Inc....
BioCentury | Nov 30, 2018
Clinical News

CHMP backs first all-oral sleeping sickness treatment, extensions for Blincyto, Opdivo-Yervoy combo

...Approval" ). CHMP also recommended Macrilen macimorelin acetate, an oral ghrelin-mimetic growth hormone secretagogue from Aeterna Zentaris Inc....
...affect other trials of Tecentriq as a monotherapy or as part of a combination therapy. Aeterna Zentaris Inc....
...ARN-509 (Compound #), apalutamide (Generic), Erleada (Other) Fexinidazole Macrilen, macimorelin acetate (AEZS-130, ard-07, macrimorelin-ghst, EP01572, EP-1572, Solorel) Opdivo/Yervoy, nivolumab/ipilimumab Aeterna Zentaris Inc. Amgen...
BioCentury | Nov 16, 2018
Company News

CHMP backs first all-oral sleeping sickness treatment, extensions for Blincyto, Opdivo-Yervoy combo

...Approval" ). CHMP also recommended Macrilen macimorelin acetate, an oral ghrelin-mimetic growth hormone secretagogue from Aeterna Zentaris Inc....
...2017 for the indication (see "Strongbridge Hands Off Macrilen to Novo for Sizeable Return" ). Aeterna's...
...ARN-509 (Compound #), apalutamide (Generic), Erleada (Other) Fexinidazole Macrilen, macimorelin acetate (AEZS-130, ard-07, macrimorelin-ghst, EP01572, EP-1572, Solorel) Opdivo/Yervoy, nivolumab/ipilimumab Aeterna Zentaris Inc. Amgen...
BioCentury | Nov 2, 2018
Company News

Strongbridge hands off Macrilen to Novo for sizable return

...$24 million to Aeterna Zentaris Inc. (NASDAQ:AEZS; TSX:AEZS) for the Macrilen rights in January. On Oct. 31, Aeterna...
...$2.18 on NASDAQ and C$1.16 (69%) to C$2.85 in Toronto. Under its deal with Strongbridge, Aeterna...
...Aeterna has Macrilen in pediatric trials, and that Novo will assume Strongbridge's financial obligation to Aeterna...
BioCentury | Oct 31, 2018
Company News

Strongbridge hands off Macrilen to Novo for sizable return

...out $24 million to Aeterna Zentaris Inc. (NASDAQ:AEZS; TSX:AEZS) for the Macrilen rights in January. On Wednesday, Aeterna...
...$2.18 on NASDAQ and C$1.16 (69%) to C$2.85 in Toronto. Under its deal with Strongbridge, Aeterna...
...Aeterna has Macrilen in pediatric trials, and that Novo will assume Strongbridge's financial obligation to Aeterna...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

...to treat solid tumors with KRAS (K-Ras), BRAF or neuroblastoma Ras viral oncogene (NRAS) mutations. Aeterna Zentaris Inc....
BioCentury | Jul 6, 2018
Company News

Management tracks: Goldman Sachs, Acceleron

...Rapperswil, Switzerland) hired Richard Sachse as global CSO. He was SVP, CSO and CMO at Aeterna Zentaris Inc....
BioCentury | May 23, 2018
Distillery Techniques

Disease models

...compared with vehicle. Next steps could include using the model to screen other PCOS therapies. Aeterna Zentaris Inc....
BioCentury | Jan 9, 2018
Finance

Stars in China

...netarsudil 0.02% to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension Aeterna Zentaris Inc....
Items per page:
1 - 10 of 547